Summary of the details of RTOG 0630 and PMH-IMRT trial ^9,10

Item	RTOG 0630	PMH-IMRT-LE-STS
Technique	3D or IMRT	IMRT alone
Anatomic site	Upper or lower extremity	Lower extremity
Chemotherapy	Cohort A: (closed Jan 2010)-induction chemotherapy (50 Gy)-concurrent chemotherapy (44 Gy)	No chemotherapy
Image guidance	2D or 3D daily image guidance	3D daily online cone-beam CT
Post-op boost (+margins)	External beam radiotherapy or brachytherapy (LDR, HDR, or IORT)	No postoperative boost
Primary end-point	Reduction of late morbidity at 2 years by RTOG/EORTC criteria (> grade 2 lymphedema, subcutaneous fibrosis, joint stiffness)	Reduction of wound complications by the SR2 criteria at 120 days
Secondary end-points	Similar between both studies	Similar between both studies
Target definitions	CTV high grade: 3 cm longitudinally; 1.5 cm axially	CTV 4 cm longitudinally: 1.5 cm axially. “Flap” is contoured as a region of interest.